Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Theranostics 6 , 12051219 (2016)
SURMOUNT-1 tirzepatide obesity trial Trial Primary trial source for tirzepatide weight-loss expectations and dose-response ranges
As the cost and regulatory barriers for new active molecules climb, companies are seeking leverage elsewhere
Proud to contribute to the scientific dialogue shaping the future of targeted protein degradation
Usually, these symptoms start to fade within a few days or weeks as your body gets used to the medicine
Finally, we also performed high-resolution TEM imaging for precise quantification of mitochondrial area and number of cristae per mitochondria in ultrathin (70-nm) sections on resin-embedded Control versus SPHKAP RNAi-treated WT INS-1 832/3 cells, as well as INS-1 832/3 GLP-1R KO cells, both under vehicle conditions and following exendin-4 stimulation
